ESOC 2023 | Global adoption of tenecteplase for acute ischemic stroke

Fouzi Bala, MD, MSc, University of Calgary, Alberta, Canada, comments on the current status of tenecteplase adoption globally. Since the publication of the pragmatic, multicenter, non-inferiority AcT trial and other supportive trials, many guidelines have been updated to recommend tenecteplase (TNK) as a suitable alternative to alteplase for patients with acute ischemic stroke matching the standard criteria for thrombolysis. Many stroke centers are switching to TNK given its numerous advantages, including its lower cost, longer half-life, easier administration, and higher fibrin specificity. This interview took place during the European Stroke Organisation Conference (ESOC) in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.